Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus
Status:
Withdrawn
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Albumin-bound paclitaxel regimen in advanced NSCLC has a better tumor response rate and
safety than solvent-based paclitaxel. However, the safety and efficacy is uncertain in
neoadjuvant therapy in esophageal cancer. The objective of this single-arm phase II trial was
to evaluate the benefit of neoadjuvant chemotherapy with nanoparticle albumin-bound
paclitaxel plus 5-fluorouracil in patients with locally advanced esophageal squamous cell
carcinoma.